FDA Panel To Weigh Unmet Need Vs. Liver Injury With Samsca Kidney Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Risk of drug-induced injury is likely to complicate an Aug. 5 advisory committee review of Otsuka’s kidney drug tolvaptan.